Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Novel Psychoactive Substances (NPS) Prevalence in Clinical Urine Specimens at Quest Diagnostics in 2024

ADLM 2025

Association for Diagnostics and Laboratory medicine

Chicago, IL, July 27-31 , 2025

Poster presentation: Novel Psychoactive Substances (NPS) Prevalence in Clinical Urine Specimens at Quest Diagnostics in 2024

Authors: Neifeld JR, Meli TM, Smith MP, Bartock SH

Medical Specialty: Prescription drug monitoring, Toxicology

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Conference Presentation
Novel Psychoactive Substances Most Commonly Identified in Clinical Specimens from November 2023 to April 2024
Publication
Workplace Mental Health: Application of a Population Health Approach of Proactive Screening to Identify Risk and Engage in Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.